JP2013511496A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511496A5
JP2013511496A5 JP2012539355A JP2012539355A JP2013511496A5 JP 2013511496 A5 JP2013511496 A5 JP 2013511496A5 JP 2012539355 A JP2012539355 A JP 2012539355A JP 2012539355 A JP2012539355 A JP 2012539355A JP 2013511496 A5 JP2013511496 A5 JP 2013511496A5
Authority
JP
Japan
Prior art keywords
composition
composition according
carbon atoms
dosage form
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012539355A
Other languages
English (en)
Japanese (ja)
Other versions
JP5707009B2 (ja
JP2013511496A (ja
Filing date
Publication date
Priority claimed from EP09014548A external-priority patent/EP2332525A1/en
Application filed filed Critical
Publication of JP2013511496A publication Critical patent/JP2013511496A/ja
Publication of JP2013511496A5 publication Critical patent/JP2013511496A5/ja
Application granted granted Critical
Publication of JP5707009B2 publication Critical patent/JP5707009B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012539355A 2009-11-23 2010-11-22 プロポフォールを含有する医薬組成物 Active JP5707009B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09014548.3 2009-11-23
EP09014548A EP2332525A1 (en) 2009-11-23 2009-11-23 Pharmaceutical composition comprising propofol
PCT/EP2010/067938 WO2011061332A1 (en) 2009-11-23 2010-11-22 Pharmaceutical composition comprising propofol

Publications (3)

Publication Number Publication Date
JP2013511496A JP2013511496A (ja) 2013-04-04
JP2013511496A5 true JP2013511496A5 (cg-RX-API-DMAC10.html) 2013-12-05
JP5707009B2 JP5707009B2 (ja) 2015-04-22

Family

ID=41694756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012539355A Active JP5707009B2 (ja) 2009-11-23 2010-11-22 プロポフォールを含有する医薬組成物

Country Status (12)

Country Link
US (1) US8796340B2 (cg-RX-API-DMAC10.html)
EP (2) EP2332525A1 (cg-RX-API-DMAC10.html)
JP (1) JP5707009B2 (cg-RX-API-DMAC10.html)
KR (1) KR20120104262A (cg-RX-API-DMAC10.html)
CN (1) CN102753159B (cg-RX-API-DMAC10.html)
AU (1) AU2010320823B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012012108A2 (cg-RX-API-DMAC10.html)
CA (1) CA2776855C (cg-RX-API-DMAC10.html)
ES (1) ES2450423T3 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN03130A (cg-RX-API-DMAC10.html)
MX (1) MX2012005881A (cg-RX-API-DMAC10.html)
WO (1) WO2011061332A1 (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CN103561724B (zh) 2011-05-25 2016-06-29 诺瓦利克有限责任公司 给药给甲的药物组合物
JP6039145B2 (ja) 2011-05-25 2016-12-07 ノバリック ゲーエムベーハー 半フッ化アルカンを基礎にした局所薬学的組成物
GB201116271D0 (en) 2011-09-21 2011-11-02 Univ Cardiff Dispersion anaesthetic device
PT2806886T (pt) 2012-01-23 2017-03-24 Novaliq Gmbh Composições de proteínas estabilizadas baseadas em alcanos semifluorados
EP2895144B1 (en) 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
MX363182B (es) 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
PL2708228T3 (pl) * 2012-09-12 2018-11-30 Novaliq Gmbh Kompozycje do przemywania oczu
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
EP2944324A1 (de) * 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
EP3206683A4 (en) 2014-10-16 2018-06-13 The Board of Trustees of the Leland Stanford Junior University Novel methods, compounds, and compositions for anesthesia
EP3722274B1 (en) 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane for ophthalmic administration
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
DK3442480T3 (da) 2016-06-23 2020-01-13 Novaliq Gmbh Fremgangsmåde til topisk indgivelse
KR102614858B1 (ko) 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
MX381639B (es) 2016-12-23 2025-03-13 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
JP7814839B2 (ja) 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
AU2019246035B2 (en) 2018-03-28 2024-07-18 Novaliq Gmbh Pharmaceutical composition comprising timolol
JP7855312B2 (ja) 2018-04-27 2026-05-08 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
CN114449999A (zh) 2019-09-06 2022-05-06 诺瓦利克有限责任公司 用于治疗葡萄膜炎的眼用组合物
EP3912622A1 (en) 2020-05-19 2021-11-24 tesa Labtec GmbH Oral film for safe administration of api

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
WO2000054588A1 (en) * 1999-03-15 2000-09-21 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
GB0124071D0 (en) * 2001-10-08 2001-11-28 Kbig Ltd Improvement in the administration of high boiling point aneasthetics
WO2005067517A2 (en) * 2004-01-02 2005-07-28 Wisconsin Alumni Research Foundation Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers
DE102004030044A1 (de) 2004-06-22 2006-01-12 Birken Gmbh Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels
US9000048B2 (en) * 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
PL2110126T3 (pl) * 2008-04-18 2012-04-30 Novaliq Gmbh Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej

Similar Documents

Publication Publication Date Title
US10639439B2 (en) Smokeless THC and administration method thereof
ES2894836T3 (es) Compuestos de CBD fluorados, composiciones y usos de los mismos
RU2009111388A (ru) Органические соединения
RU2013121788A (ru) Ингибиторы репликации вич
JP2013542247A5 (cg-RX-API-DMAC10.html)
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
JP2011500781A5 (cg-RX-API-DMAC10.html)
JP2013513586A5 (cg-RX-API-DMAC10.html)
JP2012530779A5 (cg-RX-API-DMAC10.html)
JP2015529229A5 (cg-RX-API-DMAC10.html)
RU2018135967A (ru) Интраназальные фармацевтические композиции на основе бензодиазепина
EA201401354A1 (ru) Новая дозированная форма и препарат, содержащий абедитерол
PE20091672A1 (es) Nueva dosificacion y formulacion
RU2015136849A (ru) Композиции, содержащие 15-он эпк, и способы их применения
JP2014515407A5 (cg-RX-API-DMAC10.html)
MD4369B1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
JP2015509075A5 (cg-RX-API-DMAC10.html)
AR087868A1 (es) Compuestos de triazolopiridina como moduladores de la tirosina quinasa c-met
RU2019110980A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
RU2008124825A (ru) Органические соединения, включающие соль гликопиррония
EP2476429A4 (en) PTH-CONTAINING THERAPY / PROPHYLAXIS AGENT FOR OSTEOPOROSIS ONCE PER WEEK, WITH ONE UNIT DOSE OF 100 TO 200 UNITS OF SUCCESSFUL PTH ADMINISTRATION
CN103127543A (zh) 硅酮敷料及其制备方法和用途
JP2015502371A5 (cg-RX-API-DMAC10.html)
JP2014511897A5 (cg-RX-API-DMAC10.html)
RU2010138650A (ru) Комбинация, включающая паклитаксел, для лечения рака яичников